Login Register Cart 0
Generic placeholder image

Drug Delivery Letters

Editor-in-Chief

ISSN (Print): 2210-3031
ISSN (Online): 2210-304X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Clinical Trial

Intranasal Delivery of Perillyl Alcohol (NEO100) as a New Treatment Strategy for Glioma

Author(s): Axel H. Schönthal, Julio Thome, Daniela C. de Lima, Thomas C. Chen and Clovis O. da Fonseca*

Volume 14, Issue 1, 2024

Published on: 20 December, 2023

Page: [81 - 88] Pages: 8

DOI: 10.2174/0122103031253788231020060301

Price: $65

conference banner
Abstract

Background: Perillyl alcohol (POH) is a naturally occurring monoterpene that is being developed as an intranasally delivered agent for the treatment of brain-localized malignancies. Clinical trials with glioma patients in Brazil have yielded preliminary evidence that this approach might be able to achieve therapeutic activity and result in prolonged survival of patients.

Methods: NEO100, a highly pure, current good manufacturing practice-produced version of POH, is being evaluated in a Phase I/IIa clinical trial with recurrent glioblastoma patients in the United States. Patients self-administer POH/NEO100 as a mist with a nasal mask over the course of 15 minutes, four times a day, every day.

Results: The treatment regimen is well tolerated, even if maintained over several years. It correlated with improved survival when compared to historical controls.

Conclusion: There is human data demonstrating that this novel approach could become useful for the treatment of malignant glioma.

« Previous Next »
Graphical Abstract

[1]
Sharif, Y.; Jumah, F.; Coplan, L.; Krosser, A.; Sharif, K.; Tubbs, R.S. Blood brain barrier: A review of its anatomy and physiology in health and disease. Clin. Anat., 2018, 31(6), 812-823.
[http://dx.doi.org/10.1002/ca.23083] [PMID: 29637627]
[2]
Crowe, T.P.; Greenlee, M.H.W.; Kanthasamy, A.G.; Hsu, W.H. Mechanism of intranasal drug delivery directly to the brain. Life Sci., 2018, 195, 44-52.
[http://dx.doi.org/10.1016/j.lfs.2017.12.025] [PMID: 29277310]
[3]
Crowe, T.P.; Hsu, W.H. Evaluation of recent intranasal drug delivery systems to the central nervous system. Pharmaceutics, 2022, 14(3), 629.
[http://dx.doi.org/10.3390/pharmaceutics14030629] [PMID: 35336004]
[4]
Erdő, F.; Bors, L.A.; Farkas, D.; Bajza, Á.; Gizurarson, S. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res. Bull., 2018, 143, 155-170.
[http://dx.doi.org/10.1016/j.brainresbull.2018.10.009] [PMID: 30449731]
[5]
Ostermann, S.; Csajka, C.; Buclin, T.; Leyvraz, S.; Lejeune, F.; Decosterd, L.A.; Stupp, R. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin. Cancer Res., 2004, 10(11), 3728-3736.
[http://dx.doi.org/10.1158/1078-0432.CCR-03-0807] [PMID: 15173079]
[6]
Portnow, J.; Badie, B.; Chen, M.; Liu, A.; Blanchard, S.; Synold, T.W. The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: Potential implications for the current approach to chemoradiation. Clin. Cancer Res., 2009, 15(22), 7092-7098.
[http://dx.doi.org/10.1158/1078-0432.CCR-09-1349] [PMID: 19861433]
[7]
Stupp, R.; Hegi, M.E.; Mason, W.P.; van den Bent, M.J.; Taphoorn, M.J.B.; Janzer, R.C.; Ludwin, S.K.; Allgeier, A.; Fisher, B.; Belanger, K.; Hau, P.; Brandes, A.A.; Gijtenbeek, J.; Marosi, C.; Vecht, C.J.; Mokhtari, K.; Wesseling, P.; Villa, S.; Eisenhauer, E.; Gorlia, T.; Weller, M.; Lacombe, D.; Cairncross, J.G.; Mirimanoff, R.O. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol., 2009, 10(5), 459-466.
[http://dx.doi.org/10.1016/S1470-2045(09)70025-7] [PMID: 19269895]
[8]
Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.B.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; Curschmann, J.; Janzer, R.C.; Ludwin, S.K.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J.G.; Eisenhauer, E.; Mirimanoff, R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med., 2005, 352(10), 987-996.
[http://dx.doi.org/10.1056/NEJMoa043330] [PMID: 15758009]
[9]
Chen, T.; da Fonseca, C.; Schönthal, A. Intranasal perillyl alcohol for glioma therapy: Molecular mechanisms and clinical development. Int. J. Mol. Sci., 2018, 19(12), 3905.
[http://dx.doi.org/10.3390/ijms19123905] [PMID: 30563210]
[10]
Crowell, P.L.; Elson, C.E. Isoprenoids, health and disease. In: Neutraceuticals and Functional Foods; Wildman, R.E.C., Ed.; CRC Press: Boca Raton, FL, 2001; pp. 31-54.
[11]
Chen, T.C.; da Fonseca, C.O.; Levin, D.; Schönthal, A.H. The monoterpenoid perillyl alcohol: Anticancer agent and medium to overcome biological barriers. Pharmaceutics, 2021, 13(12), 2167.
[http://dx.doi.org/10.3390/pharmaceutics13122167] [PMID: 34959448]
[12]
Durço, A.O.; Conceição, L.S.R.; de Souza, D.S.; Lima, C.A.; Quintans, J.S.S.; Viana dos Santos, M.R. Perillyl alcohol as a treatment for cancer: A systematic review. Phytomedicine Plus, 2021, 1(3), 100090.
[http://dx.doi.org/10.1016/j.phyplu.2021.100090]
[13]
Gould, M.N. Cancer chemoprevention and therapy by monoterpenes. Environ. Health Perspect., 1997, 105(Suppl. 4), 977-979.
[14]
Bailey, H.H.; Attia, S.; Love, R.R.; Fass, T.; Chappell, R.; Tutsch, K.; Harris, L.; Jumonville, A.; Hansen, R.; Shapiro, G.R.; Stewart, J.A. Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer. Cancer Chemother. Pharmacol., 2008, 62(1), 149-157.
[http://dx.doi.org/10.1007/s00280-007-0585-6] [PMID: 17885756]
[15]
Bailey, H.H.; Levy, D.; Harris, L.S.; Schink, J.C.; Foss, F.; Beatty, P.; Wadler, S. A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96. Gynecol. Oncol., 2002, 85(3), 464-468.
[http://dx.doi.org/10.1006/gyno.2002.6647] [PMID: 12051875]
[16]
Liu, G.; Oettel, K.; Bailey, H.; Ummersen, L.V.; Tutsch, K.; Staab, M.J.; Horvath, D.; Alberti, D.; Arzoomanian, R.; Rezazadeh, H.; McGovern, J.; Robinson, E.; DeMets, D.; Wilding, G. Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer. Invest. New Drugs, 2003, 21(3), 367-372.
[http://dx.doi.org/10.1023/A:1025437115182] [PMID: 14578686]
[17]
Meadows, S.M.; Mulkerin, D.; Berlin, J.; Bailey, H.; Kolesar, J.; Warren, D.; Thomas, J.P. Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer. Int. J. Gastrointest. Cancer, 2002, 32(2-3), 125-128.
[http://dx.doi.org/10.1385/IJGC:32:2-3:125] [PMID: 12794248]
[18]
Chen, T.C.; Fonseca, C.O.; Schönthal, A.H. Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy. Am. J. Cancer Res., 2015, 5(5), 1580-1593.
[PMID: 26175929]
[19]
Da Fonseca, C.O.; Masini, M.; Futuro, D.; Caetano, R.; Rocha Gattass, C.; Quirico-Santos, T. Anaplastic oligodendroglioma responding favorably to intranasal delivery of perillyl alcohol: A case report and literature review. Surg. Neurol., 2006, 66(6), 611-615.
[http://dx.doi.org/10.1016/j.surneu.2006.02.034] [PMID: 17145324]
[20]
Schönthal, A.H.; Swenson, S.; Bonney, P.A.; Wagle, N.; Simmon, V.F.; Mathew, A.J.; Hurth, K.M.; Chen, T.C. Detection of perillyl alcohol and its metabolite perillic acid in postsurgical glioblastoma tissue after intranasal administration of NEO100: Illustrative case. J Neurosurg Case Lessons, 2022, 4(8), CASE22215.
[http://dx.doi.org/10.3171/CASE22215] [PMID: 36088606]
[21]
Ripple, G.H.; Gould, M.N.; Stewart, J.A.; Tutsch, K.D.; Arzoomanian, R.Z.; Alberti, D.; Feierabend, C.; Pomplun, M.; Wilding, G.; Bailey, H.H. Phase I clinical trial of perillyl alcohol administered daily. Clin. Cancer Res., 1998, 4(5), 1159-1164.
[PMID: 9607573]
[22]
Nehra, G.; Andrews, S.; Rettig, J.; Gould, M.N.; Haag, J.D.; Howard, S.P.; Thorne, R.G. Intranasal administration of the chemotherapeutic perillyl alcohol results in selective delivery to the cerebrospinal fluid in rats. Sci. Rep., 2021, 11(1), 6351.
[http://dx.doi.org/10.1038/s41598-021-85293-4] [PMID: 33737566]
[23]
da Fonseca, C.O.; Schwartsmann, G.; Fischer, J.; Nagel, J.; Futuro, D.; Quirico-Santos, T.; Gattass, C.R. Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. Surg. Neurol., 2008, 70(3), 259-266.
[http://dx.doi.org/10.1016/j.surneu.2007.07.040] [PMID: 18295834]
[24]
da Fonseca, C.O.; Simão, M.; Lins, I.R.; Caetano, R.O.; Futuro, D.; Quirico-Santos, T. Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma. J. Cancer Res. Clin. Oncol., 2011, 137(2), 287-293.
[http://dx.doi.org/10.1007/s00432-010-0873-0] [PMID: 20401670]
[25]
DA Fonseca, C.O.; Teixeira, R.M.; Silva, J.C.; DE Saldanha DA Gama Fischer, J.; Meirelles, O.C.; Landeiro, J.A.; Quirico-Santos, T. Long-term outcome in patients with recurrent malignant glioma treated with Perillyl alcohol inhalation. Anticancer Res., 2013, 33(12), 5625-5631.
[PMID: 24324108]
[26]
Schönthal, A.H.; Peereboom, D.M.; Wagle, N.; Lai, R.; Mathew, A.J.; Hurth, K.M.; Simmon, V.F.; Howard, S.P.; Taylor, L.P.; Chow, F.; da Fonseca, C.O.; Chen, T.C. Phase I trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastoma. Neurooncol. Adv., 2021, 3(1), vdab005.
[http://dx.doi.org/10.1093/noajnl/vdab005] [PMID: 33604574]
[27]
Boon, P.J.M.; van der Boon, D.; Mulder, G.J. Cytotoxicity and biotransformation of the anticancer drug perillyl alcohol in PC12 cells and in the rat. Toxicol. Appl. Pharmacol., 2000, 167(1), 55-62.
[http://dx.doi.org/10.1006/taap.2000.8988] [PMID: 10936079]
[28]
Shimada, T.; Shindo, M.; Miyazawa, M. Species differences in the metabolism of (+)- and (-)-limonenes and their metabolites, carveols and carvones, by cytochrome P450 enzymes in liver microsomes of mice, rats, guinea pigs, rabbits, dogs, monkeys, and humans. Drug Metab. Pharmacokinet., 2002, 17(6), 507-515.
[http://dx.doi.org/10.2133/dmpk.17.507] [PMID: 15618705]
[29]
Haag, J.D.; Gould, M.N. Mammary carcinoma regression induced by perillyl alcohol, a hydroxylated analog of limonene. Cancer Chemother. Pharmacol., 1994, 34(6), 477-483.
[http://dx.doi.org/10.1007/BF00685658] [PMID: 7923558]
[30]
Field, K.M.; Simes, J.; Nowak, A.K.; Cher, L.; Wheeler, H.; Hovey, E.J.; Brown, C.S.B.; Barnes, E.H.; Sawkins, K.; Livingstone, A.; Freilich, R.; Phal, P.M.; Fitt, G.; Rosenthal, M.A. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. Neuro-oncol., 2015, 17(11), 1504-1513.
[http://dx.doi.org/10.1093/neuonc/nov104] [PMID: 26130744]
[31]
Heiland, D.H.; Masalha, W.; Franco, P.; Machein, M.R.; Weyerbrock, A. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine. J. Neurooncol., 2016, 126(3), 567-575.
[http://dx.doi.org/10.1007/s11060-015-2002-z] [PMID: 26614518]
[32]
Taal, W.; Oosterkamp, H.M.; Walenkamp, A.M.E.; Dubbink, H.J.; Beerepoot, L.V.; Hanse, M.C.J.; Buter, J.; Honkoop, A.H.; Boerman, D.; de Vos, F.Y.F.; Dinjens, W.N.M.; Enting, R.H.; Taphoorn, M.J.B.; van den Berkmortel, F.W.P.J.; Jansen, R.L.H.; Brandsma, D.; Bromberg, J.E.C.; van Heuvel, I.; Vernhout, R.M.; van der Holt, B.; van den Bent, M.J. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): A randomised controlled phase 2 trial. Lancet Oncol., 2014, 15(9), 943-953.
[http://dx.doi.org/10.1016/S1470-2045(14)70314-6] [PMID: 25035291]
[33]
Batchelor, T.T.; Mulholland, P.; Neyns, B.; Nabors, L.B.; Campone, M.; Wick, A.; Mason, W.; Mikkelsen, T.; Phuphanich, S.; Ashby, L.S.; DeGroot, J.; Gattamaneni, R.; Cher, L.; Rosenthal, M.; Payer, F.; Jürgensmeier, J.M.; Jain, R.K.; Sorensen, A.G.; Xu, J.; Liu, Q.; van den Bent, M. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J. Clin. Oncol., 2013, 31(26), 3212-3218.
[http://dx.doi.org/10.1200/JCO.2012.47.2464] [PMID: 23940216]
[34]
Reardon, D.A.; Brandes, A.A.; Omuro, A.; Mulholland, P.; Lim, M.; Wick, A.; Baehring, J.; Ahluwalia, M.S.; Roth, P.; Bähr, O.; Phuphanich, S.; Sepulveda, J.M.; De Souza, P.; Sahebjam, S.; Carleton, M.; Tatsuoka, K.; Taitt, C.; Zwirtes, R.; Sampson, J.; Weller, M. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma. JAMA Oncol., 2020, 6(7), 1003-1010.
[http://dx.doi.org/10.1001/jamaoncol.2020.1024] [PMID: 32437507]
[35]
Abbott, N.J. Blood–brain barrier structure and function and the challenges for CNS drug delivery. J. Inherit. Metab. Dis., 2013, 36(3), 437-449.
[http://dx.doi.org/10.1007/s10545-013-9608-0] [PMID: 23609350]
[36]
Arvanitis, C.D.; Ferraro, G.B.; Jain, R.K. The blood–brain barrier and blood–tumour barrier in brain tumours and metastases. Nat. Rev. Cancer, 2020, 20(1), 26-41.
[http://dx.doi.org/10.1038/s41568-019-0205-x] [PMID: 31601988]
[37]
Hendricks, B.K.; Cohen-Gadol, A.A.; Miller, J.C. Novel delivery methods bypassing the blood-brain and blood-tumor barriers. Neurosurg. Focus, 2015, 38(3), E10.
[http://dx.doi.org/10.3171/2015.1.FOCUS14767] [PMID: 25727219]
[38]
Agrawal, M.; Saraf, S.; Saraf, S.; Antimisiaris, S.G.; Chougule, M.B.; Shoyele, S.A.; Alexander, A. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J. Control. Release, 2018, 281, 139-177.
[http://dx.doi.org/10.1016/j.jconrel.2018.05.011] [PMID: 29772289]
[39]
Keller, L.A.; Merkel, O.; Popp, A. Intranasal drug delivery: Opportunities and toxicologic challenges during drug development. Drug Deliv. Transl. Res., 2022, 12(4), 735-757.
[http://dx.doi.org/10.1007/s13346-020-00891-5] [PMID: 33491126]
[40]
Xu, J.; Tao, J.; Wang, J. Design and application in delivery system of intranasal antidepressants. Front. Bioeng. Biotechnol., 2020, 8, 626882.
[http://dx.doi.org/10.3389/fbioe.2020.626882] [PMID: 33409272]
[41]
Bose, M.; Farias Quipildor, G.; Ehrlich, M.E.; Salton, S.R. Intranasal peptide therapeutics: A promising avenue for overcoming the challenges of traditional CNS drug development. Cells, 2022, 11(22), 3629.
[http://dx.doi.org/10.3390/cells11223629] [PMID: 36429060]
[42]
Duong, V.A.; Nguyen, T.T.L.; Maeng, H.J. Recent advances in intranasal liposomes for drug, gene, and vaccine delivery. Pharmaceutics, 2023, 15(1), 207.
[http://dx.doi.org/10.3390/pharmaceutics15010207] [PMID: 36678838]
[43]
Lockman, P.R.; Mittapalli, R.K.; Taskar, K.S.; Rudraraju, V.; Gril, B.; Bohn, K.A.; Adkins, C.E.; Roberts, A.; Thorsheim, H.R.; Gaasch, J.A.; Huang, S.; Palmieri, D.; Steeg, P.S.; Smith, Q.R. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin. Cancer Res., 2010, 16(23), 5664-5678.
[http://dx.doi.org/10.1158/1078-0432.CCR-10-1564] [PMID: 20829328]
[44]
Sarkaria, J.N.; Hu, L.S.; Parney, I.F.; Pafundi, D.H.; Brinkmann, D.H.; Laack, N.N.; Giannini, C.; Burns, T.C.; Kizilbash, S.H.; Laramy, J.K.; Swanson, K.R.; Kaufmann, T.J.; Brown, P.D.; Agar, N.Y.R.; Galanis, E.; Buckner, J.C.; Elmquist, W.F. Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro-oncol., 2018, 20(2), 184-191.
[http://dx.doi.org/10.1093/neuonc/nox175] [PMID: 29016900]
[45]
Upton, D.H.; Ung, C.; George, S.M.; Tsoli, M.; Kavallaris, M.; Ziegler, D.S. Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy. Theranostics, 2022, 12(10), 4734-4752.
[http://dx.doi.org/10.7150/thno.69682] [PMID: 35832071]
[46]
Gänger, S.; Schindowski, K. Tailoring formulations for intranasal nose-to-brain delivery: A review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa. Pharmaceutics, 2018, 10(3), 116.
[http://dx.doi.org/10.3390/pharmaceutics10030116] [PMID: 30081536]
[47]
Pardridge, W.M. The blood-brain barrier: Bottleneck in brain drug development. NeuroRx, 2005, 2(1), 3-14.
[http://dx.doi.org/10.1602/neurorx.2.1.3] [PMID: 15717053]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy